253P Real-world adherence and tolerability of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: Analysis from a large comprehensive cancer center
D. Napetti, T. Giarratano, M. Bottosso, G. Faggioni, C. Falci, G. Griguolo, F. Miglietta, C.A. Giorgi, F. Girardi, A. Menichetti, P. Napolitano, M. La Commare, M.V. Dieci, V. Guarneri
原始摘要（英文原文）· Original abstract
Adjuvant abemaciclib significantly improves invasive disease-free survival and overall survival in patients (pts) with high-risk HR+/HER2- breast cancer (BC). Toxicity management and treatment adherence remain key issues in clinical practice, and real world data may provide insights into treatment optimization.
253P Real-world adherence and tolerability of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: Analysis from a large comprehensive cancer center — 科研速览 Science Skim